Keywords: Tumors (Pre-Treatment), Translational Studies, Treatment response, Survival prediction, Glioblastoma (GBM), Perfusion, Quantitative Imaging
Motivation: Quantitative measurements at baseline, prior to chemoradiation, can inform prognosis and optimal treatment strategies for patients with glioblastoma (GBM), however, such measurements using ASL are currently lacking.
Goal(s): To investigate ASL measured quantitative perfusion prior to chemoradiation for survival prediction in GBM patients.
Approach: Twenty-three newly diagnosed GBM patients were enrolled in this prospective IRB-approved study. Baseline scans with ASL and survival information were obtained.
Results: ASL measured baseline perfusion aids in survival prediction and stratification between groups with long (mean: 717 days) and short (mean: 361 days) survival in GBM.
Impact: Early and accurate survival stratification by ASL measured perfusion prior to chemoradiation treatment provides valuable opportunities for therapeutic interventions, including personalized and biologically driven radiation treatment planning and strategic discontinuation of traditional treatments for enrollment in promising clinical trials.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords